Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AccuTheranostics, Inc. logo — Elevating personalized chemotherapy for cancer patients with...

AccuTheranostics, Inc.

Elevating personalized chemotherapy for cancer patients with advanced, patient-specific diagnostics and prognostics.

Founded 2012 2 employees Convertible Note Biotechnology

General Information

Company Name AccuTheranostics, Inc.
Founded Year 2012
Employees 2
Industries Biotechnology
Funding Stage Convertible Note
Social

Get notified when AccuTheranostics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AccuTheranostics, Inc.

AccuTheranostics, Inc. is a biotechnology startup founded in 2012 with a mission to revolutionize personalized chemotherapy for cancer patients. Their slogan, "Elevating personalized chemotherapy for cancer patients with advanced, patient-specific diagnostics and prognostics," encapsulates their key focus. The company specializes in providing tailored treatment through a range of laboratory tests. Their flagship service, ChemoFit™, is an innovative lab test that uses a patient’s own tumor cells to identify the most effective chemotherapy drugs. This personalized approach allows physicians to select treatments with the highest potential while avoiding those to which the patient’s tumor is resistant. The last investment, a Convertible Note, was secured on 01 January 2017 from Launch NY. AccuTheranostics' disruptive approach to cancer treatment and its focus on individualized care makes it a promising player in the biotechnology industry.

Taxonomy: oncology, cancer diagnostics, prognostics, chemotherapy, personalized medicine, cellular makeup, drug testing, tumor analysis, precision medicine, patient-specific treatment, chemoresistance, patient outcomes, therapeutics

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 1 •••• •••• 01 Jan 2017

AccuTheranostics, Inc. Alternatives & Competitors

AccuTheranostics, Inc. vs
Biocept, Inc.
Biocept, Inc. United States

Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic...

Post Ipo Equity
49 employees
Biotechnology, Health Care
AccuTheranostics, Inc. vs
ASC Oncology GmbH
ASC Oncology GmbH Germany

RETHINK ONCOLOGY

7 employees
Biotechnology, Health Care
AccuTheranostics, Inc. vs
Nagourney Cancer Institute
Nagourney Cancer Institute

With 20+ years of research, Dr. Nagourney has developed the Ex Vivo Analysis of Programmed Cell Deat...

9 employees
Biotechnology, Health Care

FAQ About AccuTheranostics, Inc.

Elevating personalized chemotherapy for cancer patients with advanced, patient-specific diagnostics and prognostics.
AccuTheranostics, Inc. was founded in 2012.
AccuTheranostics, Inc. operates in the following industries: Biotechnology.
AccuTheranostics, Inc. has approximately 2 employees.
AccuTheranostics, Inc. has completed 1 funding round. The latest funding stage is Convertible Note.
Top alternatives and competitors to AccuTheranostics, Inc. include Biocept, Inc. , ASC Oncology GmbH, Nagourney Cancer Institute, Pyxis Diagnostics, Navignostics AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AccuTheranostics, Inc. and Biocept, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AccuTheranostics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy